Brain Cancer

Midline Glioblastoma

Female, 36 years

Patient Internal 434626791

ICD-10 code

C71.7 Malignant Neoplasm of Brain Stem

Diagnosis (Incl. Metastases/Stage) and Year

May 2021
Midline Glioma, WHO Grade 4, likely H3K27M Mutation, IDH1/2 mutations not detected, TERT (-).
Disease progression in June 2023.

Previous Treatment

Surgery, Radiation Therapy, Chemotherapy (Temozolomide), Chemotherapy (Lomustine).

Prognosis and Survival Expectation

The prognosis remains poor, with a median survival of ~14 months from diagnosis.

Treatment Provided

Autologous DCV (4 doses) and CIK (16 doses) over a period of 14 months.

Patient Survival/Condition and Year
Date of Review: 15/11/2023

The patient has survived for 29 months. It can be concluded that the addition of Immunotherapy, alongside Surgery, Radiation Therapy and Chemotherapy, has benefited in disease stabilisation and extended survival by an estimate of 15 months so far.